Ability Biotherapeutics Moves to Inspire Bio Innovations in Montreal, Pioneering the New Generation of Targeted Antibodies
Article content
MONTREAL — Ability Biotherapeutics, a Quebec-based leader in antibody therapeutics, is proud to announce its new location at Inspire Bio Innovations. The company will occupy the 6th floor of Phase 2 in the transformative redevelopment of the former Montreal Chest Institute, marking a significant step in its growth within Montreal's thriving life sciences ecosystem.
Article content
Article content
The project's first phase is scheduled for completion this summer, with the second phase, including Ability's new space, expected to wrap up by the end of 2026. Ability Biotherapeutics is pioneering a new generation of targeted antibody therapies for cancer and autoimmune diseases, powered by its proprietary generative AI-based AbiLeap™ platform. Ability is advancing multiple drug discovery programs, with three lead programs now entering optimization and development as it prepares for preclinical studies. Taking advantage of Inspire Bio Innovations' dynamic environment, Ability plans to complete preclinical studies to demonstrate the effectiveness of its therapeutic products and to begin large-scale production in preparation for the first human clinical trials. These steps are expected to enable the company to triple its number of employees by 2028.
Article content
Since its unveiling less than two years ago, the Inspire project has sparked genuine enthusiasm within the life sciences ecosystem. Initially hosting the headquarters of Cellcarta, it has since brought together various Montreal universities and the Montreal Clinical Research Institute (IRCM). The project gained international recognition by being awarded the title of Future Office Project of the Year at the prestigious World Architecture Festival (WAF). This life sciences hub is already attracting a community of forward-thinking researchers and entrepreneurs focused on innovation, and continues to welcome companies from around the world seeking to thrive in its dynamic environment.
Article content
Located in the heart of downtown Montreal, Inspire Bio Innovations offers an ideal location with easy access via public and active transportation and proximity to major highways. This life sciences innovation hub is strategically located near a vibrant community of research centres and top-tier researchers, including MILA, CR-CHUM, CR-CUSUM, IRCM, and IRIC. This proximity will significantly enhance interactions and knowledge sharing. Additionally, being close to major hospitals like CHUM and MUHC will streamline the execution of local clinical studies. These factors make Inspire Bio Innovations highly attractive for retaining current talent and recruiting global experts.
Article content
'We are excited to pursue our activities within Inspire Bio Innovations, a cutting-edge hub that fosters exchanges and interactions with top-tier researchers and innovative entrepreneurs. The collaborative environment created by Jadco is ideal for advancing the development of therapies with the potential to transform the treatment of patients with cancer or autoimmune diseases, both in Québec and globally.'—Patrick Tremblay, Ph.D., Chief Operating Officer at Ability Biotherapeutics.
Article content
'We firmly believe that Inspire Bio Innovations is the ideal hub for nurturing the next generation of researchers and innovators who will propel the entire life sciences ecosystem forward. Montreal possesses all the attributes necessary to strengthen its role as one of the most dynamic and promising international centres in this field. This new space, dedicated to innovation and precision medicine, will unite talented teams whose work will continue this tradition while facilitating the commercialization of discoveries.'—Normand Rivard, Managing Partner, Life Sciences and Innovation, Jadco Group.
Article content
'Ability Biotherapeutics' addition to the Inspire Bio Innovations scientific hub once again demonstrates the excellence of this innovation centre dedicated to scientific research. This new partnership strengthens the project's leading role in biotechnology. We are delighted to see this promising collaboration take shape in Plateau-Mont-Royal.'—Luc Rabouin, Leader of Projet Montréal.
Article content
About Ability Biotherapeutics
Ability Biotherapeutics is the next-generation biotherapeutics company developing logic-gated antibodies with exceptional contextual selectivity and stability, driving safer, more effective immunotherapies for cancer and autoimmune diseases. Its proprietary platform, AbiLeap™, uses generative AI powered by one of the largest and exclusively held, therapeutically relevant human antibody databases, providing distinct insights for sequence space exploration. Combining AI with in vitro display and screening technologies, AbiLeap™ generates fully human antibodies that are conditionally activated and multi-specific, directing therapeutic targeting to specific cells and disease sites. This approach enables solutions for indications with high unmet clinical needs by reducing toxicity and significantly broadening the therapeutic window, maximizing treatment benefits. Ability's experienced team is committed to revolutionizing targeted therapeutics to transform patient outcomes and redefine industry standards. www.ability.bio
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Winnipeg Free Press
6 hours ago
- Winnipeg Free Press
TACO time
Opinion The stock market says, 'Yes.' And the bond market says, 'No.' This sums up much of the recent sentiment about the economy in the United States, and for that matter the global economy, amid the back-and-forth policies of U.S. President Donald Trump. Stocks have largely recovered their losses this year, as investors believe the One Big Beautiful Bill Act — with its tax cuts largely focused on the wealthy — will power a surge in growth. Michael Probst / The Associated Press files The curve of the German stock index DAX is seen in the background as U.S. President Donald Trump is shown on a TV screen at the stock market in Frankfurt, Germany. What's more, many investors ascribe to 'TACO', a term coined by a Financial Times columnist that stands for 'Trump always chickens out,' meaning most of the tariffs threats are bluster meant to make him appear to be a master deal-maker and they won't be here to stay. 'That is quite a diverging opinion from what the bond market is saying,' says Jonathan Baird, Toronto-based editor and publisher of the Global Investment Letter. Bond investors view the One Big Beautiful Bill as a recipe for inflation, eventually adding more than US$3.8 trillion to the annual budget deficit. Tariffs, too, are inflationary, which further make the case for more investors to sell their U.S. bonds. Average investors, not Wall Street, are likely feeling indecisive and maybe even fearful. A dose of caution is warranted, says John De Goey, portfolio manager with Design Wealth Management in Toronto, and author of Stand Up to the Financial Services Industry. Even without Trump-induced mayhem, 'stocks are very expensive and therefore very risky.' He points to the cyclically adjusted price-to-earnings — or CAPE — for the S&P 500. CAPE helps determine if an investment — based on a 10-year average of inflation-adjusted earnings — is valued appropriately. Right now, the S&P 500 is highly overvalued, according to CAPE. De Goey says the metric may not be a good predictor of bear markets. 'But it's extremely reliable for determining what the annualized return will be for the asset class … over the next decade,' he says. 'So when the S&P 500 is in the 30s or higher, the return over the next decade has historically been around zero.' The CAPE for the world's largest stock index has been about 35 in recent weeks. What's more, many seasoned investors see a decade ahead that could be similar to the 1970s when 'stagflation' weighed on markets. Characterized by higher than normal inflation and slow economic growth, stagflation can be toxic for stock and bond returns. 'I would suggest probably being as defensive as you're comfortable being,' says Baird, who expects stagflation to be a problem for the next few years. He doesn't recommend moving all of the portfolio to cash to preserve capital. That is tricky to time correctly on getting out of the market and, even more so, getting back into the market. Broadly, stagflation fighting strategies should focus less on growth stocks. Instead, consider companies selling goods and services consumers can't go without — like groceries and housing. Bonds should have shorter durations to reduce the impact of inflation. Commodity- and currency-based strategies can also provide some upside amid volatility. As well, alternative investments — private equity and credit, private real estate and hedge funds — are increasingly used by portfolio managers. 'The low-hanging fruit is increasing alternatives exposure,' De Goey says, noting these assets are less correlated to stock and bond markets, providing portfolio stability. Previously only available to wealthy investors, alternatives are now widely available as mutual funds and exchange-traded funds (ETFs). That said, investors should still own stocks, including those in the U.S., but they should consider reducing exposure to overvalued companies like the so-called Magnificent Seven (including Amazon Inc., Tesla Inc., Apple Inc. and Meta Inc.), says Jai Gandhi, investment adviser with Endeavour Wealth Management, iA Private Wealth in Winnipeg. 'We're not cutting our weight to the U.S. market compared with a year ago, but we're conscious of the high values of companies that hold more risk.' That said, owning good companies never goes out of style for long-term investors. 'We don't worry too much about short-term price movements,' says Hardev Bains, president and chief investment officer at Lionridge Capital Management in Winnipeg. Rather, the focus for Bains and other fundamental investors is owning companies with long-term profitability growth, strong balance sheets (significantly more assets than liabilities) and competitive advantages. These companies, however, are only purchased when their share price reflects fair value relative to those qualities. What's more, even holding great companies can be risky when they become steeply overvalued. At that point, it's worthwhile selling those holdings or at least reducing their portion in the portfolio. 'Part of our discipline is if we sell companies and can't find anything to buy — which happens in periods of expensive markets — we go to cash, as we're doing right now,' Bains says Companies may have great business models, but their share price today is generally too high to purchase with a margin of safety. Still, Lionridge's equity portfolio obviously must hold stocks — currently about 20 companies that are likely to weather stagflation and even a recession better than other stocks. A recession is likely already underway, De Goey notes, pointing to gross domestic product (GDP) in the first quarter contracting in the U.S. 'No reasonable person expects the economy to grow in Q2 given tariffs are now having more of an impact.' Monday Mornings The latest local business news and a lookahead to the coming week. The best companies should remain profitable, and market drops will put their shares on sale from time to time, Baird says. In the meantime, beware of FOMO — fear of missing out — when markets surge higher, he adds. That often leads to buying high and, worse, selling low in a knee-jerk reaction to markets plunging in fear. 'We're all fallible and prone to psychological traps,' Baird adds. 'So the biggest thing for any investor is managing our emotions.' Joel Schlesinger is a Winnipeg-based freelance journalist joelschles@
CTV News
8 hours ago
- CTV News
Laval and police brotherhood sign ‘bold' new collective agreement
The City of Laval and the Police Brotherhood signed a new collective agreement for the Laval Police Service on Friday—a deal Mayor Stéphane Boyer described as 'fairly bold, fairly innovative compared to other police forces.' The agreement, in principle, was ratified by 78 per cent of the police brotherhood's members. It includes the transfer of certain administrative duties to civilian staff, freeing up 20,000 additional investigative hours for police officers—at a lower cost to the city. The new contract also introduces the deployment of cadets across Laval to manage traffic, representing another salary-saving measure for the municipality. In terms of compensation, the agreement includes salary increases totalling 22.2 per cent over five years. This figure combines base wage hikes with 'urban security premiums' tied to the unique challenges officers face in large urban centres. The city also aimed to boost police presence on the streets to strengthen residents' sense of safety. In an interview, Mayor Boyer said he was particularly proud of the deal. 'What we were looking for was greater efficiency and more officers on the streets. This agreement allows us to achieve that. And in my view, it's quite a bold and innovative deal compared to other police forces—recovering thousands of hours of investigation and street presence. We're really pleased with the outcome, and I think it's going to be a win-win, both for the officers and for the public,' said Boyer. Sylvain Tardif, president of the Laval Police Brotherhood, also welcomed the new agreement, saying it 'recognizes the dedication and professionalism officers bring to their work every day in keeping Laval residents safe.' 'The new contract offers working conditions that reflect the growing responsibilities of our officers, who work in a complex environment and are facing an evolving and increasingly sophisticated criminal landscape,' Tardif added. Pierre Brochet, director of the Laval Police Service, also noted that the new agreement will allow police to 'fight crime more effectively, while ensuring a stronger presence in the community.' The collective agreement will be in effect from Jan. 1, 2024, to Dec. 31, 2028. This report by The Canadian Press was first published in French on June 6, 2025. By Lia Lévesque, The Canadian Press
CTV News
8 hours ago
- CTV News
Quebec open to extending inquiry into SAAQclic
Commissioner Denis Gallant of the Commission of Inquiry into the Management of the Modernization of the Société de l'assurance automobile (SAAQ) IT Systems is awaiting the start of the public inquiry into the failures of the SAAQclic platform in Montreal on Thursday, April 24 2025. A public inquiry into the SAAQ's costly digital transformation has revealed that it could cost the province nearly half a billion dollars more than originally anticipated. (The Canadian Press/Christinne Muschi)
